Kiniksa Pharmaceuticals International, plc
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Sanj K. Patel
- Full Time Employees
- 366
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 105 Piccadilly London GL United Kingdom W1J 7NJ
- IPO Date
- May 24, 2018
- CIK
- 0001730430
- Website
- kiniksa.com
- Similar Companies
- Business
- Kiniksa Pharmaceuticals International, plc (KNSA) is a commercial-stage biopharmaceutical company that discovers, acquires, develops and commercializes therapeutic medicines for patients with debilitating diseases featuring significant unmet medical needs, with a primary focus on cardiovascular and inflammatory indications worldwide. The company markets ARCALYST (rilonacept), an interleukin-1 alpha and beta inhibitor approved for treating recurrent pericarditis, an inflammatory cardiovascular disease; its pipeline includes vixarelimab, a monoclonal antibody in Phase 2b trials for chronic inducible urticaria and other pruritic skin diseases; KPL-387, a preclinical Fc-modified immunoglobulin G2 monoclonal antibody that received FDA Orphan Drug Designation for pericarditis; and other early-stage candidates targeting unmet needs in immunology and beyond. Founded in 2015 and headquartered in London, United Kingdom, with primary U.S. operations in Lexington, Massachusetts, the company maintains additional facilities in Zug, Switzerland, and La Jolla, California, supporting global development and commercialization efforts. In June 2024, Kiniksa Pharmaceuticals, Ltd. changed its name to Kiniksa Pharmaceuticals International, plc to reflect its expanded international presence; recent highlights include robust ARCALYST net product revenue growth of 61% year-over-year to $180.9 million in Q3 2025, raised full-year 2025 sales guidance to $560-$580 million, a return to profitability with $18.4 million net income in Q3 2025, and pipeline advancement via FDA Orphan Drug Designation for KPL-387 in pericarditis.
Company News
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High – Still a Buy?
10,232 Shares of Kiniksa Pharmaceuticals International, plc $KNSA Acquired by B. Riley Wealth Advisors Inc.
Head-To-Head Survey: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Mirum Pharmaceuticals (NASDAQ:MIRM)
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock Has Consensus Price Target of $87.38 According to Brokerages
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
5 Stocks With Recent Price Strength Despite Recent Market Volatility
Recent Price Trend in Kiniksa Pharmaceuticals International, plc (KNSA) is Your Friend, Here's Why
4 Top-Ranked Stocks With Solid Net Profit Margins to Boost Your Gains
Kiniksa Pharmaceuticals International, plc (KNSA) Is a Great Choice for 'Trend' Investors, Here's Why
What Makes Kiniksa Pharmaceuticals International, plc (KNSA) a Strong Momentum Stock: Buy Now?